Tranquility Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Tranquility Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$259K	Buy	+496	New	+$254K	0.09%	196

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

Tranquility Partners's VRTX Position: Q3 2026 in Review

Tranquility Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 496 shares worth $259K. The stake represents 0.09% of the portfolio and ranks #196 among its holdings.

347 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Tranquility Partners held 496 shares of Vertex Pharmaceuticals worth $259K as of Q3 2026.
Vertex Pharmaceuticals was a new Tranquility Partners position in Q3 2026.
Vertex Pharmaceuticals made up 0.09% of Tranquility Partners's portfolio in Q3 2026, its #196 holding.
347 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Tranquility Partners's 13F filing for Q3 2026, filed 20 Oct 2026.